S.C. Odontostomatologia - Azienda Ospedaliera "Ordine Mauriziano di Torino"
Turin, 10128, Italy
NCT Number: NCT06293911
The aim of the study is to evaluate the efficacy of home treatment with a postbiotic-based gel for the management of periodontal inflammation in patients with Down syndrome.
Patients will be enrolled at the S.C. Odontostomatologia dell'Azienda Ospedaliera "Ordine Mauriziano di Torino", Turin, Italy. After the collection of the periodontal clinical indexes (BoP%, PCR%, dental mobility, mMGI, compliance and satisfaction questionnaire), patients will undergo a professional mechanical debridement with ultrasonic instruments and glycine powders.
Then, they will be randomly divided into two groups according to the home treatment:
* in the Trial group Biorepair Plus Parodontgel Intensive (containing microRepair®, hyaluronic acid, Lactobacillus Ferment and Aloe Barbadensis Leaf Juice Powder) will be used once a day for all the duration of the study * in the Control group, a placebo gel without (active ingredients) will be used once a day for all the duration of the study.
Indexes will be re-evaluated after 1 (T1), 3 (T2) and 6 months. The professional mechanical debridement will be performed again at T3 timepoint.
Looking for future studies?
Notify Me18 year–70 year
All sexes
Interventional
Not applicable
Turin, 10128, Italy
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Biorepair Plus Parodontgel Intensive gel will be used after home oral hygiene once a day.
The placebo gel (without hyaluronic acid, Lactobacillus Ferment, Aloe Barbadensis Leaf Juice Powder and lactoferrin) will be used after home oral hygiene once a day.
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
Dichotomous scoring (yes/no) of bleeding sites on 4 surfaces of teeth.
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
% assessment of the amount of plaque on dental surfaces; it is detected on 4 surfaces: distal, mesial, vestibular, lingual / palatal. The number of sites with plaque is divided by the total number of sites available in the mouth and multiplied by 100. Results indicate the index as a percentage.
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
Scoring criteria
Grade 0: oscillation within 0.2 mm; the teeth move naturally and there are no mobility problems; Grade I: horizontal mobility of the tooth from 0.2 to 1 mm; Grade II: horizontal mobility of the tooth from 1 to 2 mm; Grado III: horizontal mobility equal to or greater than 3 mm or vertical mobility of the tooth.
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
Scoring criteria (one measurement for each tooth: upper first incisors, first premolars/first primary molars and first molars):
Mild inflammation (marginal or papillary unit) Mild inflammation (entire marginal and papillary unit) Moderate inflammation Severe inflammation
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
Subjective evaluation of the patient's degree of compliance with the proposed treatment by Visual Analogue Scale (VAS), assessing compliance with dosage, alterations and modifications on lifestyle, and adherence to set recalls; to which is associated a score from 0 to 10 of which:
Time frame: Baseline (T0), after 1 month (T1), 3 months (T2) and after 6 months (T3)
University of Pavia
Other
Clinical Comparison of a Postbiotic-gel With Placebo Gel for Gingival Inflammation in Patients With Down Syndrome: Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07702201
Abnormalities, Multiple, Chromosome Disorders
Giza, Eldoky, Egypt
View Trial DetailsNCT05662228
Abnormalities, Multiple, Autoimmune Diseases
Los Angeles, California, United States
View Trial DetailsNCT06592404
Abnormalities, Multiple, Autism Spectrum Disorder
Sittard, Limburg, Netherlands
View Trial DetailsNCT06206824
Abnormalities, Multiple, Alzheimer Disease
Gières, France
View Trial Details